<SEC-DOCUMENT>0001193125-17-242416.txt : 20170731
<SEC-HEADER>0001193125-17-242416.hdr.sgml : 20170731
<ACCEPTANCE-DATETIME>20170731162804
ACCESSION NUMBER:		0001193125-17-242416
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170728
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170731
DATE AS OF CHANGE:		20170731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		17993308

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d435910d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July 28, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Dynavax Technologies Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission
File <FONT STYLE="white-space:nowrap">Number:&nbsp;001-34207</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0728374</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2929 Seventh Street, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Berkeley, CA 94710-2753 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) (510) <FONT STYLE="white-space:nowrap">848-5100</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the Registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.03.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;31, 2017, the stockholders of the Company approved an amendment to the Company&#146;s Sixth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#146;s common stock, par value $0.001
from 69,500,000 shares to 139,000,000 shares. The increase in authorized shares was effected pursuant to a Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (the &#147;Certificate of Amendment&#148;), filed with
the Secretary of State of the State of Delaware on July&nbsp;31, 2017. A copy of the Certificate of Amendment is attached as Exhibit 3.1 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated into this Item
5.03 by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.07.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Submission of Matters to a Vote of Security Holders </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2017, the Company
held its Special Meeting of Stockholders (the &#147;Special Meeting&#148;), at the Company&#146;s executive office in Berkeley, California. A total of 54,747,656 shares of the Company&#146;s common stock were entitled to vote as of June&nbsp;30,
2017, the record date for the Special Meeting. There were 43,316,072 shares present in person or by proxy at the Special Meeting, at which the stockholders were asked to vote on two (2)&nbsp;proposals. Set forth below are the matters acted upon by
the stockholders, and the final voting results of each such proposal. The proposals are described in detail in the Company&#146;s Proxy Statement for a Special Meeting of Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposal 1. Amend the Company&#146;s Sixth Amended and Restated Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders approved to amend the Company&#146;s Sixth Amended and Restated Certificate of Incorporation, as amended, to increase the
authorized number of shares of common stock from 69,500,000 to 139,000,000. The votes were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:12.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Against</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Abstain</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">35,935,589</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6,888,876</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">491,607</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposal 2. Authorize an adjournment of the meeting, if necessary, to solicit additional proxies if there are
not sufficient votes in favor of Proposal 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders approved to authorize an adjournment, if necessary, to solicit additional
proxies if there are not sufficient votes I favor of Proposal 1. The votes were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:12.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Against</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Abstain</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">35,058,281</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7,918,240</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">339,551</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;28, 2017, Dynavax Technologies Corporation issued a press
release titled &#147;Dynavax Announces FDA Advisory Committee Vote in Favor of <FONT STYLE="white-space:nowrap">HEPLISAV-B&#153;.&#148;</FONT> A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. The following exhibits are filed
herewith: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top">Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">99.1</TD>
<TD ALIGN="left" VALIGN="top">Press Release, dated July&nbsp;28, 2017, titled &#147;Dynavax Announces FDA Advisory Committee Vote in Favor of <FONT STYLE="white-space:nowrap">HEPLISAV-B&#153;&#148;</FONT> </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Dynavax Technologies Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;31, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ STEVEN N. GERSTEN</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Steven N. Gersten</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">EX-3.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">EX-99.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated July&nbsp;28, 2017, titled &#147;Dynavax Announces FDA Advisory Committee Vote in Favor of <FONT STYLE="white-space:nowrap">HEPLISAV-B&#153;&#148;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d435910dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DYNAVAX TECHNOLOGIES CORPORATION</B>, a corporation organized and existing under and by virtue of the General Corporation Law of the State
of Delaware (the &#147;<B><I>Corporation</I></B>&#148;), hereby certifies that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>: The name of the Corporation
is<B>&nbsp;DYNAVAX TECHNOLOGIES CORPORATION</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: The Corporation was originally incorporated under the same name and the
original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on November&nbsp;6, 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIRD</B>: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections&nbsp;141 and 242 of the General
Corporation Law of the State of Delaware, adopted resolutions to amend its Sixth Amended and Restated Certificate of Incorporation as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Article IV shall be amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The Corporation is authorized to issue two classes of stock to be designated, respectively, Common Stock and Preferred Stock. The
Corporation shall be authorized to issue 139,000,000 shares of Common Stock at $0.001 par value, and 5,000,000 shares of Preferred Stock at $0.001 par value. The Preferred Stock may be issued from time to time in one or more series pursuant to a
resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board). The rights, preferences, privileges and restrictions granted to or imposed upon the Preferred
Stock or any series of Preferred Stock will be determined or altered by the Board of Directors. The Board of Directors shall have the authority to fix or alter the number of shares of any series of Preferred Stock and the designation of any such
series of Preferred Stock. The Board of Directors, within the limits and restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, may increase or decrease (but not
below the number of shares in any such series then outstanding), the number of shares of any series subsequent to the issue of shares of that series.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOURTH:</B>&nbsp;Thereafter pursuant to a&nbsp;resolution of the Board of Directors, this Certificate of Amendment was submitted to the
stockholders of the Corporation for their approval, and was duly adopted at the Special Meeting of Stockholders held on July&nbsp;31, 2017 in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State of Delaware.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer this 31st
day of July, 2017. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DYNAVAX&nbsp;TECHNOLOGIES&nbsp;CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Eddie Gray</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Eddie&nbsp;Gray,&nbsp;Chief&nbsp;Executive&nbsp;Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d435910dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g435910g0731122225455.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dynavax Announces FDA Advisory Committee </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vote in Favor of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT><SUP STYLE="font-size:85%; vertical-align:top">&#153; </SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BERKELEY, Calif. &#150; July</B><B></B><B>&nbsp;28, 2017</B> <B>&#150;</B> Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S.
Food and Drug Administration&#146;s&nbsp;(FDA) Vaccines and Related Biological Products Advisory Committee&nbsp;(VRBPAC) voted 12 to 1 that the safety data for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> [Hepatitis B Vaccine, Recombinant
(Adjuvanted)] support licensure for immunization against hepatitis B infection in adults 18 years of age and older. Three members of the panel abstained. Additionally, the Committee provided commentary on the design of Dynavax&#146;s proposed
post-marketing pharmacovigilance plan for <FONT STYLE="white-space:nowrap">HEPLISAV-B.</FONT> The FDA did not ask this VRBPAC panel to vote on the immunogenicity of <FONT STYLE="white-space:nowrap">HEPLISAV-B.</FONT> A prior VRBPAC panel voted 13 to
1 that the data from Phase 3 clinical trials supports the immunogenicity of <FONT STYLE="white-space:nowrap">HEPLISAV-B.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged
by the committee&#146;s positive vote in favor of <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> which we believe will become an important new tool in the fight against hepatitis B infection if approved by the FDA,&#148; said Eddie Gray, chief
executive officer of&nbsp;Dynavax. &#147;Clinical studies of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> have shown that the vaccine provides increased rates of seroprotection. In addition, the <FONT STYLE="white-space:nowrap">two-dose</FONT>
regimen offers the potential to increase patient compliance, which physicians and advocates agree is essential to preventing more cases of hepatitis B and achieving the public health goal of eradication. We look forward to completing our ongoing
discussions with the FDA regarding an appropriate post-marketing commitment as it finalizes its review.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incidence of hepatitis B in the U.S. is
increasing<SUP STYLE="font-size:85%; vertical-align:top">i</SUP> and there is no cure for the disease. Therefore, disease prevention through effective vaccination is critical to reducing its spread. Currently marketed hepatitis B vaccines are
administered in three doses over a <FONT STYLE="white-space:nowrap">six-month</FONT> schedule. The <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> regimen is two doses over one month. Results of a published Vaccine Safety Datalink study showed
that only 54&nbsp;percent of adults completed the currently available three-dose hepatitis B vaccine series in one year.<SUP STYLE="font-size:85%; vertical-align:top">ii</SUP> Those who do not complete the series may not be adequately protected
against hepatitis B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA is not bound by the committee&#146;s recommendation but takes its advice into consideration when reviewing marketing
applications. <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> has a Prescription Drug User Fee Act (PDUFA) date of August&nbsp;10, 2017. If the FDA approves <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> Dynavax will seek a recommendation
from the Centers for Disease Control and Prevention&#146;s (CDC) Advisory Committee on Immunization Practices (ACIP) during its October 2017 meeting. Dynavax plans to launch the vaccine commercially in the U.S. in early 2018 on its own or through a
commercial partner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Hepatitis B </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hepatitis B
is a viral disease of the liver that can become chronic and can lead to cirrhosis of the liver, hepatocellular carcinoma and death. In the U.S., the number of reported cases of acute hepatitis B increased more than 20&nbsp;percent in 2015.<SUP
STYLE="font-size:85%; vertical-align:top">iii</SUP> After adjusting for under-reporting, the CDC estimated that 21,900 new hepatitis B virus infections occurred in 2015. In addition to new cases of hepatitis B, chronic HBV infection remains a major
public health challenge. The CDC estimates that approximately 850,000 persons are living with hepatitis B virus in the U.S. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary
Toll-like Receptor 9 agonist to enhance the immune response. In Phase 3 trials, <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> showed higher and earlier protection with fewer doses than a currently licensed hepatitis B vaccine. The most
frequently reported local reaction was injection site pain. The most common systemic reactions were fatigue, headache and malaise, all of which were similar to an existing vaccine. Dynavax has worldwide commercial rights to <FONT
STYLE="white-space:nowrap">HEPLISAV-B.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Dynavax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dynavax is a clinical-stage immunology company focused on leveraging the power of the body&#146;s innate and adaptive immune responses through toll-like
receptor (TLR) stimulation. Dynavax is developing product candidates for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax&#146;s lead product candidates are <FONT
STYLE="white-space:nowrap">SD-101,</FONT> an investigational cancer immunotherapeutic currently in Phase 1/2 studies, and <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> a Phase 3 investigational adult hepatitis B vaccine. For more information,
visit www.dynavax.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking&#148; statements, including statements regarding <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and FDA
review. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the FDA will find the response to the Complete Response Letter (CRL) to be satisfactory to support
approval; whether the FDA will require additional information or studies; whether the FDA will identify additional issues following review of Dynavax&#146;s response to the CRL; whether the FDA will decide not to approve <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> despite a positive recommendation of the Vaccines and Related Biological Products Advisory Committee; whether the FDA will delay approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B;</FONT> whether
additional manufacturing process enhancements will be required or other issues will arise that will negatively impact the review and approval by the FDA; whether the issues will negatively impact the potential scope of the label for <FONT
STYLE="white-space:nowrap">HEPLISAV-B;</FONT> the nature and scope of any post-marketing study that the FDA will require; whether the Centers for Disease Control and Prevention&#146;s Advisory Committee on Immunization will provide a recommendation
for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> if approved by the FDA; and other risks detailed in the &#147;Risk Factors&#148; section of our most recent current periodic report filed with the SEC. We do not undertake any obligation to
update publicly any such forward-looking statements, even if new information becomes available. Information on Dynavax&#146;s website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ryan Spencer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Corporate Strategy&nbsp;&amp; Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">510.665.4618
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>rspencer@dynavax.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leslie Bryant, WCG </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">562.505.9290 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lbryant@w2ogroup.com </U></P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">i</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">https://www.cdc.gov/hepatitis/statistics/2015surveillance/commentary.htm#Ref10. Accessed July&nbsp;5, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">ii</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nelson JC, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents and adults: Results from a Vaccine Safety Datalink study. Am J Public Health. 2009;99(S2); S389-S397.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">iii</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">https://www.cdc.gov/hepatitis/statistics/2015surveillance/commentary.htm#Ref10. Accessed July&nbsp;5, 2017. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g435910g0731122225455.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g435910g0731122225455.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O -8# 2(  A$! Q$!_\0
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MYBNK#_\ (TK>B_0I?Q&7&(52S$  9)/:OGSQ1JDOB#Q%>WL:L\2'"8&=L:G
M/^?6O6?B%K7]D>&)D1L3W?[E,=0#]X_E_.N>^'/AF*X\/7]U=ID7ZF!<CD)W
M/Y_RKZW!M4*;KR]$>9CU+$U8X:'J_P!/Z\SH/AYK7]K>&(HY&S/:?N7]2!]T
M_EQ^%8OQ6T7S]/M]7B7YX#Y<I']T]#^!_G7/>";R7PQXWETNZ.U)G-N^>F[/
MRG\_YUZ]J-C%J6G7%E,,QSQE#[9[TJO^SXE3CL]?DRZ'^UX-TY?$M/FMCG_A
M_K7]L>%X0[9GM?W,F>I ^Z?R_D:ZFO&O E]+X<\9S:3=G8DS&!P>@<'Y3_3\
M:]AGGCMK>2>5@L<:EV8]@!DUCC*7)5]W9ZHWP%?VE!<V\='\CS/XKZR2;718
M6_Z;3 ?DH_F?RKL?!NC#0_#-K;LN)I!YLW^\W;\!@?A7F?A^"3QE\07O9U)A
M60SR ] J_=7^0KVB6188GD<X5 23[5IC&J-*-'MJS#!?OJL\2_1>AS'BV]W-
M%9(<X^=P/7M_GWJ#PM=M;WTEG)D"3H#V85%ID;ZQX@:>0916\QOPZ#^5/\06
M[:?K$=Y%\HD(<'T8=?\ /O7Y_*I5E4>9KX5*W_;NW]>9V7=^<[.L+Q)I?VRU
M^TQK^^B'..Z__6K7M;A;JUCG3[KJ#]*FKZBO1IXJ@X/:2_X9F[2DK'->%]4W
MI]@F;YEYC)].XI/%&J;$^P0M\S<R8].PK-UNR?2-36XMSM1SO3'8]Q2Z)9/J
MVIM<W!W(AWOGN>PKYGZSB?9_V;;W[VO_ '?Z_ QYI6Y#:\-Z6+2T^T2K^^F'
M&>RT5NT5]1AL/##TE2ALC>*25CB?"?\ R%F_ZY-_,5VU>=6,E[I\YFAC8,5*
M\KFM+^VM9E^54.?9*^;RO,J6%P_LYQ=[O9&%.:BK,V/$]XD.F-!N'F2D #V!
MS3/"ENT6F/(PQYCY'T''^-9=IH5]J5P)KYF5#R2W4UU\420Q+%&NU%& *[\'
M"KB<6\74CRI*R3W+BG*7,QS*KH58 JPP0>]<'I]M$WB58&7,8E88^F<?RKO:
MXS3X91XJ#F-@OG2<X_WJ,WIJ56A=7][_ ""HM4=G6)XJ_P"0/_VT'\C6W6-X
MG1GTG:BDGS!P![&N_,E?"5/1ES^%AX7_ .0*O^^U8^OZ6UA<B^M05C+9.W^%
MJV?#2,FCJK*0=YX-:LT,=Q"\4JAD<8(KBC@HXK+Z<'HTE9]F1R\T$CBM7U--
M2TZT8D"9"P=?RYKJ])_Y!-K_ -<Q7%:GI,]C>-$J,Z'E6 ZBNDNM0?2?!QND
M1FF2#$:@9)8\#]:Y<G]M4QT_:KWK)?=9$1ERMRET1YOXWO9?$OC:'2K4[DA<
M6Z8Z;B?F/^?2O7=/LHM.T^WLX!B.&,(OX5YE\,]"GEUBYU>]B<&$;4WCDNW4
M_E_.O5J^RQLE'EHQVC^9R9="4N;$3WD_P/)OBEI#6FJ6NM0 J)<)(1V=>A_+
M^5>A^&M776_#]I? C>Z;9!Z..#3?%&D+KGAZ[LL R%=T1]''(_P_&N'^%UW=
MV=W=:5=0RI'(/,C+*0 PX(_$?RJF_;87SA^7]?D))X?&_P!V?Y_U^94^*&DO
M8ZS;:U;@J)L!V7M(O0_B/Y5?\6^+UN_ 5EY+@7&H#;* ?NA?O_K79>*]'&N>
M'+JS"YEV[XO]\<C\^GXUXGI&@W^IZM:6#PS)&TF"64X5?XC^5=&&<*M.+F]8
M?E_7Y')C%4H591IK2I^?]?F>H?#/1?[.\/?;9%Q->G=SU"#[O]3^-;'BF^\B
MP6W4X>8\_P"Z*VX84MX(X8E"QQJ%4#L!TKCKV.;6/$ 78PBW; 2.BCJ?YU\O
MGN*G*FU#XINR_K\#UH4U1HJG$K:5J\FEQNL=NK%SDL<T_4]:EU.V$4ELJ[6W
M!AG(KM!:VZJ%$,> ,#Y12_9H/^>,?_?(KSEE&*5'V/MO=[6+]G*UKG/^$KW?
M#)9L>4^=/IW_ ,^]=&[K&C.Y 51DD]JXR2"71O$/F1HQA#9X'53V_P ^E:7B
M6^E,0L[=6.X NP';L*>#QKPV$G"JO>INWKV_KL$9<L=>AD74LWB#65CCR(\[
M5_V5]:+2:7P_K+129\O.UO=?6M_PYI?V*T\^1?WTHSSV%'B/2_MMIY\2_OHA
MV_B%<G]GU_8?7;_O;\WR[?UZ$\CMS=3:1UD170@JPR".]%<YX=U!XX&M;H,H
M091B.WI17OX7&4Z])5+VOT-HR35SH\#T%+@>E%%=A04R2:.$*9)%3>P1=QQE
MCT'UI]8GB3F+3/\ L)0?^A54(\TK$5)<L6S3^W6I@DF%Q%Y43%7?<,*1P033
MEN;=GF598RT/^M 893C//IQ7F]Y:7%GX=U*^MCNM[JZFBNXF;@'SB%D7W[$=
M^/2M*\M;B+4/$>K67,T,FR>(MA98?(3(^HZC\1WKI^K1[_UI_F<BQ<NL?ZU_
MR.QGU2PM88I9[R&..49C9G ##U%2I=6\L@C2:-W*"0*&!)4]#]*X2"]LM!73
M[_6(?-M+G3+>*WDVA_+*I\R;>V<@YIL\-[HFB6>M6T2QS+)+&D!<?+#,28US
M_LMM./<T?5UM??\ $/K;W:VW[I?UJ=U]OLPBO]IAV/)Y2G>,%\XV_7VJ.76-
M-@N3;RWUNDP.#&T@#9^E<5=Z+=W;1Z-8Q1R1Z7; ,[RE/])D&[S!P<D=?^!5
MI6<T.K:MH%[+;1>;);7'G90']XNP'Z\@XI.A%*]_ZW7WH:Q$V[6MM_D_N9U
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'!12T4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
